Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCLAT1 | Q6UWP7 | 17/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 4/20 | 0.79 |
| ▸ | LMNA | P02545 | 3/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21867354 | 0.95 | LCLAT1 (0.81) | LCLAT1MAPK1MAPTLMNANPSR1 | |
| SCHEMBL21866862 | 0.93 | LCLAT1 (0.80) | LCLAT1MAPK1MAPTLMNANPSR1 | |
| SCHEMBL21866337 | 0.91 | LCLAT1 (0.82) | LCLAT1MAPK1MAPTLMNANPSR1 | |
| SCHEMBL21866518 | 0.91 | LCLAT1 (0.82) | LCLAT1MAPK1MAPTLMNANPSR1 | |
| SCHEMBL21867401 | 0.90 | LCLAT1 (0.80) | LCLAT1MAPK1MAPTLMNANPSR1 | |
| SCHEMBL21867286 | 0.90 | LCLAT1 (0.91) | LCLAT1MAPK1MAPTLMNANPSR1 | |
| SCHEMBL21866813 | 0.90 | LCLAT1 (0.83) | LCLAT1MAPK1MAPTLMNANPSR1 | |
| SCHEMBL21866799 | 0.90 | LCLAT1 (0.87) | LCLAT1MAPK1MAPTLMNANPSR1 | |
| SCHEMBL21866158 | 0.90 | LCLAT1 (1.00) | LCLAT1MAPK1MAPTLMNANPSR1 | |
| SCHEMBL21866849 | 0.89 | LCLAT1 (0.82) | LCLAT1MAPK1MAPTLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208404-B2 | Compounds useful as inhibitors of ALCAT 1 | PERENNA PHARMACEUTICALS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200109136-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 | PERENNA PHARMACEUTICALS, INC. | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208404-B2 | Compounds useful as inhibitors of ALCAT 1 | ACAT1, ACAT2, SLC33A1 | LCLAT1 5/4885MAPK1 1909/4885MAPT 333/4885 |
| US-20200109136-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 | ACAT1, ACAT2, SLC33A1 | LCLAT1 5/4885MAPK1 1909/4885MAPT 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.